JP2022513700A5 - - Google Patents
Info
- Publication number
- JP2022513700A5 JP2022513700A5 JP2021531492A JP2021531492A JP2022513700A5 JP 2022513700 A5 JP2022513700 A5 JP 2022513700A5 JP 2021531492 A JP2021531492 A JP 2021531492A JP 2021531492 A JP2021531492 A JP 2021531492A JP 2022513700 A5 JP2022513700 A5 JP 2022513700A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- combination
- formula
- tumor
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774847P | 2018-12-03 | 2018-12-03 | |
| US62/774,847 | 2018-12-03 | ||
| PCT/IB2019/001342 WO2020115556A1 (en) | 2018-12-03 | 2019-12-03 | Radioimmunoconjugates and checkpoint inhibitor combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513700A JP2022513700A (ja) | 2022-02-09 |
| JP2022513700A5 true JP2022513700A5 (cg-RX-API-DMAC7.html) | 2023-10-25 |
Family
ID=70973593
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531492A Pending JP2022513700A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とチェックポイント阻害剤の併用療法 |
| JP2021531486A Pending JP2022511471A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法 |
| JP2024193520A Pending JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531486A Pending JP2022511471A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法 |
| JP2024193520A Pending JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法 |
Country Status (18)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3125197A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| ES3075769T3 (en) | 2019-05-10 | 2026-08-07 | Janssen Biotech Inc | Macrocyclic chelators and methods of use thereof |
| TW202131946A (zh) * | 2020-01-10 | 2021-09-01 | 加拿大商融合製藥公司 | 持續性免疫療法 |
| WO2021207086A1 (en) * | 2020-04-06 | 2021-10-14 | Fusion Pharmaceuticals Inc. | Tem-1-targeted radioimmunoconjugates and uses thereof |
| CA3195512A1 (en) | 2020-10-14 | 2022-04-21 | Vahe Bedian | Compositions and methods for treatment of thyroid eye disease |
| WO2022087023A1 (en) * | 2020-10-19 | 2022-04-28 | Baruch S. Blumberg Institute | Methods and kits for diagnosing and treating cancers |
| WO2022169634A1 (en) * | 2021-02-02 | 2022-08-11 | Unm Rainforest Innovations | Combination therapy for the treatment of cancer |
| JP2024521418A (ja) * | 2021-06-11 | 2024-05-31 | フュージョン ファーマシューティカルズ インコーポレイテッド | 放射性免疫複合体とチェックポイント阻害剤併用療法 |
| US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| JP2024531151A (ja) | 2021-08-10 | 2024-08-29 | ビリジアン セラピューティクス, インコーポレイテッド | 甲状腺眼疾患の処置のための組成物、用量および方法 |
| KR20240049818A (ko) * | 2021-08-17 | 2024-04-17 | 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 | 병용 방사선요법 |
| US20250339571A1 (en) * | 2021-08-27 | 2025-11-06 | Actinium Pharmaceuticals, Inc. | Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer |
| WO2023049985A1 (en) * | 2021-09-29 | 2023-04-06 | National Research Council Of Canada | Egfrviii-targeted compounds and uses thereof |
| AU2022379928A1 (en) * | 2021-11-02 | 2024-05-09 | Fusion Pharmaceuticals Inc. | Methods of treating cancer |
| JP2025503215A (ja) * | 2022-01-28 | 2025-01-30 | フュージョン ファーマシューティカルズ インコーポレイテッド | Ntsr1標的化放射性医薬品およびdna損傷応答阻害剤併用療法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5053503A (en) * | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US7736651B1 (en) * | 2000-11-24 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Alpha emitting constructs and uses thereof |
| CA2593212A1 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Cripto binding molecules |
| JP2009532027A (ja) * | 2006-03-28 | 2009-09-10 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗igf−1r抗体およびその使用 |
| US9556272B2 (en) * | 2009-11-11 | 2017-01-31 | The Trustees Of The University Of Pennsylvania | Anti-TEM1 antibodies and uses thereof |
| IN2012DN03354A (cg-RX-API-DMAC7.html) | 2009-12-02 | 2015-10-23 | Immunomedics Inc | |
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| KR20190072663A (ko) * | 2014-04-25 | 2019-06-25 | 리나트 뉴로사이언스 코프. | 약물이 고도로 로딩된 항체-약물 접합체 |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| EP3280439A1 (en) * | 2015-04-07 | 2018-02-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Anti-pd-l1 immunotoxin for use in therapy |
| US11149087B2 (en) * | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| AU2016252038B2 (en) * | 2015-04-20 | 2021-08-12 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| US20180169230A1 (en) * | 2015-05-29 | 2018-06-21 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| JP7012645B2 (ja) * | 2016-01-11 | 2022-01-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラタンパク質および免疫治療の方法 |
| EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| US11633506B2 (en) * | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| WO2018031507A1 (en) | 2016-08-09 | 2018-02-15 | Angimmune, Llc | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| ES3071660T3 (en) * | 2016-08-24 | 2026-06-24 | Scinopharm Taiwan Ltd | Processes for preparing olaparib |
| CA3035262A1 (en) * | 2016-09-16 | 2018-03-22 | Tina Christine Lavranos | Antibody and checkpoint inhibitor combination therapy |
| JPWO2018110515A1 (ja) * | 2016-12-12 | 2019-10-24 | 第一三共株式会社 | 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| WO2018153975A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| WO2018204872A2 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| AU2018261888B2 (en) * | 2017-05-05 | 2022-06-30 | Centre For Probe Development And Commercialization | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
| US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| EP3681541A4 (en) * | 2017-09-13 | 2021-05-26 | Radimmune Therapeutics, Inc. | MELANINE ANTIBODIES AND USES THEREOF |
| CN111372613A (zh) * | 2017-11-22 | 2020-07-03 | 诺帝克纳诺维科特公司 | 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤 |
| WO2020169537A1 (en) * | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
-
2019
- 2019-12-03 KR KR1020217020517A patent/KR20210099073A/ko not_active Ceased
- 2019-12-03 EA EA202191557A patent/EA202191557A1/ru unknown
- 2019-12-03 KR KR1020217020519A patent/KR20210099074A/ko not_active Ceased
- 2019-12-03 MA MA054399A patent/MA54399A/fr unknown
- 2019-12-03 AU AU2019394888A patent/AU2019394888A1/en active Pending
- 2019-12-03 WO PCT/IB2019/001342 patent/WO2020115556A1/en not_active Ceased
- 2019-12-03 MX MX2021006408A patent/MX2021006408A/es unknown
- 2019-12-03 EP EP19893184.2A patent/EP3890790A4/en active Pending
- 2019-12-03 US US16/619,432 patent/US11446401B2/en active Active
- 2019-12-03 PE PE2021000808A patent/PE20211961A1/es unknown
- 2019-12-03 CA CA3119917A patent/CA3119917A1/en active Pending
- 2019-12-03 CN CN202311139310.7A patent/CN117482261A/zh active Pending
- 2019-12-03 SG SG11202105112RA patent/SG11202105112RA/en unknown
- 2019-12-03 CN CN202510572446.XA patent/CN120393061A/zh active Pending
- 2019-12-03 BR BR112021010670-7A patent/BR112021010670A2/pt unknown
- 2019-12-03 AU AU2019393257A patent/AU2019393257A1/en active Pending
- 2019-12-03 JP JP2021531492A patent/JP2022513700A/ja active Pending
- 2019-12-03 JP JP2021531486A patent/JP2022511471A/ja active Pending
- 2019-12-03 WO PCT/IB2019/001292 patent/WO2020115548A1/en not_active Ceased
- 2019-12-03 MA MA054401A patent/MA54401A/fr unknown
- 2019-12-03 CN CN201980079705.8A patent/CN113164632A/zh active Pending
- 2019-12-03 MX MX2021006407A patent/MX2021006407A/es unknown
- 2019-12-03 SG SG11202105192WA patent/SG11202105192WA/en unknown
- 2019-12-03 CA CA3119915A patent/CA3119915A1/en active Pending
- 2019-12-03 US US16/619,433 patent/US20220088231A1/en active Pending
- 2019-12-03 EP EP19892173.6A patent/EP3890789A4/en active Pending
- 2019-12-03 BR BR112021010799-1A patent/BR112021010799A2/pt not_active Application Discontinuation
- 2019-12-03 CN CN201980079758.XA patent/CN113474014A/zh active Pending
- 2019-12-03 PE PE2021000815A patent/PE20211286A1/es unknown
- 2019-12-03 EA EA202191556A patent/EA202191556A1/ru unknown
-
2021
- 2021-05-20 ZA ZA2021/03429A patent/ZA202103429B/en unknown
- 2021-05-28 PH PH12021551237A patent/PH12021551237A1/en unknown
- 2021-05-28 PH PH12021551282A patent/PH12021551282A1/en unknown
- 2021-06-01 IL IL283598A patent/IL283598A/en unknown
- 2021-06-01 CL CL2021001433A patent/CL2021001433A1/es unknown
- 2021-06-01 IL IL283613A patent/IL283613A/en unknown
- 2021-06-01 CL CL2021001432A patent/CL2021001432A1/es unknown
- 2021-06-02 US US17/337,357 patent/US20210290789A1/en not_active Abandoned
- 2021-06-02 US US17/337,358 patent/US20210290788A1/en not_active Abandoned
-
2022
- 2022-08-15 US US17/819,911 patent/US20230270895A1/en not_active Abandoned
-
2024
- 2024-11-05 JP JP2024193520A patent/JP2025013486A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bidkar et al. | Actinium-225 targeted alpha particle therapy for prostate cancer | |
| US20240335572A1 (en) | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging | |
| JP2020518674A5 (cg-RX-API-DMAC7.html) | ||
| Novak-Hofer et al. | Copper-67 as a therapeutic nuclide for radioimmunotherapy | |
| JP2022511471A5 (cg-RX-API-DMAC7.html) | ||
| EP2914302B1 (en) | Radiolabelled antibody and uses thereof | |
| RU2019139434A (ru) | Моноклональные антитела против igf-1r и их применение | |
| PL216208B1 (pl) | Zastosowanie kompozycji leczniczej zawierającej niesprzężone i sprzężone przeciwciała w immunoterapii nowotworów złośliwych i choroby autoimmunizacyjnej | |
| JP2020507571A (ja) | 免疫petイメージングのための放射標識抗lag3抗体 | |
| JP2020518673A5 (cg-RX-API-DMAC7.html) | ||
| EP1763372B1 (en) | Radionuclides for medical use | |
| JP7836270B2 (ja) | 抗dota/抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのdota-ハプテン組成物 | |
| JP2025039567A (ja) | 二重特異性結合因子およびその使用 | |
| CN114555132A (zh) | 放射性金属标记抗体的制造方法 | |
| JP2024091815A (ja) | 疾患または状態を処置するための組成物およびそれらの使用 | |
| US20220378956A1 (en) | Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use | |
| TW201627286A (zh) | 放射性醫藥複合物 | |
| Song et al. | Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model | |
| CN117836011A (zh) | 将生物制剂与多种螯合剂组合的方法和材料 | |
| CN113795511B (zh) | 抗pd-l1双抗体及其用途 | |
| WO2026037323A1 (zh) | 放射性核素标记的靶向pd-l1小蛋白及其制备方法与应用 | |
| JP2024521418A5 (cg-RX-API-DMAC7.html) | ||
| KR20220125330A (ko) | 지속 면역요법 | |
| JP2018168068A (ja) | 抗ポドプラニン抗体及び抗体薬物複合体 | |
| Rousseau et al. | Radiolabeled antibodies for cancer radioimmunotherapy |